A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/675 (2006.01) A61K 31/513 (2006.01) A61P 31/18 (2006.01) A61K 9/20 (2006.01) A61K 9/48 (2006.01)
Patent
CA 2512475
The present invention relates to therapeutic combinations of [2-(6-amino-purin- 9~ yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R, 5S, cis)-4-amino-5- fluoro-l-(2~ hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, EmtrivaTM, (-)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.
L'invention concerne des combinaisons thérapeutiques de diisopropoxycarbonyloxyméthyl ester d'acide [2-(6-amino-purin-9-yl)-1-méthyl-éthoxyméthyl]-phosphonique (tenofovir disoproxil fumarate, Viread®) et de (2R, 5S, cis)-4-amino-5-fluoro-l-(2- hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva<SP>TM</SP>, (-)-cis FTC) et leurs dérivés physiologiquement fonctionnels. Ces combinaisons peuvent être utilisées pour traiter des infections par le VIH, comprenant les infections à mutants du VIH résistant à des inhibiteurs nucléosidiques et/ou non nucléosidiques. L'invention concerne également des compositions pharmaceutiques et des formulations de combinaisons de tenofovir disoproxil fumarate et d'emtricitabine et leurs dérivés physiologiquement fonctionnels ainsi que des méthodes thérapeutiques utilisant ces compositions et ces formulations.
Dahl Terrence C.
Menning Mark M.
Oliyai Reza
Gilead Sciences Inc.
Robic
LandOfFree
Compositions and methods for combination antiviral therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for combination antiviral therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for combination antiviral therapy will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1616240